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Abstract
Background: Human papillomavirus (HPV) is the most prevalent genital infection, especially in young women of
reproductive age. In vitro and animal model experiments provide compelling evidence of the harmful effect of HPV
on pregnancy outcomes, but results from epidemiologic studies are inconclusive. We aim to determine the
strength of the relationship between adverse pregnancy outcomes (APO) and HPV infection and assess its
consistency across studies, by systematically reviewing the literature.
Methods: The search strategy has been developed on the basis of the PICOS framework: Population (pregnant
women); Exposure (HVP infection confirmed by HPV testing); Comparator (pregnant women without HPV infection);
Outcomes (miscarriage, spontaneous preterm birth, low birth weight, preterm premature rupture of membranes,
pregnancy-induced hypertensive disorders and intrauterine growth restriction) and Study design (observational
studies). We will search three information sources: (1) electronic databases (MEDLINE, EMBASE, and EBM Reviews
databases); (2) Grey literature (Google Scholar and Web of Science conference proceedings); and (3) citing and cited
articles of included studies. Two reviewers (JN, NZ) will independently and in duplicate screen identified articles,
select eligible studies, and extract data. Discrepancies will be resolved by consensus and otherwise by discussion
with the other authors (MHM, HT). Quality of included studies will be assessed using the Effective Public Health
Practice Project (EPHPP) Quality Assessment Tool for Quantitative Studies. We will narratively synthesize extracted
data whether meta-analysis is conducted or not. Meta-analysis of each outcome will be performed, and where
appropriate, an average measure of association will be computed. We will use the Grading of Recommendations
Assessment, Development and Evaluation (GRADE) approach to assess and grade the strength of confidence in
cumulative estimate.
Discussion: Comprehensive and high-quality evidence of a negative effect of HPV on pregnancy outcomes might
be an additional motivation for HPV vaccination. Absence of such relationship could dispel anxiety and reassure
HPV-infected pregnant women and clinicians. Findings of a poor level of confidence will allow identification of
current knowledge gaps on HPV-pregnancy outcome relationship that need further research.
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Background
Human papillomavirus (HPV) is the most common
sexually transmitted infection in adults [1, 2]. The life-
time probability of genital HPV acquisition is estimated
to be more than 80% in both women and men by the
age of 45 years [2]. The highest incidence rates occur in
young adults, just after the onset of sexual activity [3].
Longitudinal studies in young women 17–24 years of
age-reported incidence rates ranging from 15.7 to 29.4
HPV infections of all types per 1000 women-months [4].
Cohort studies of women in their thirties showed a
lower incidence rate, between 5.2 and 13.4 HPV infec-
tions any type per 1000 women-months [4].
Similarly, the prevalence is higher in younger than in
older age groups. A multi-country meta-analysis estimated
the global HPV prevalence at 11.7% (confidence interval
95% 11.6%-11.7%) in women with normal cytology with
an important variation within and between geographic re-
gions [5]. The prevalence peaks at around 25 years and
decreases thereafter. In some populations, a smaller sec-
ond peak is observed at 45 years [5, 6].
In men, the prevalence estimates of genital HPV infec-
tion vary widely across studies ranging from 1 to 84%
[7]. Unlike in women, the HPV prevalence curve in men
peaks at older ages and remains steady high or decreases
slightly with increasing age [7].
Fortunately, almost 80% of HPV infections resolve
spontaneously within 1–2 years [8]. However, accumulat-
ing evidence suggests that HPV infection is more likely to
persist during pregnancy [9] and regress after delivery
[10–13]. Indeed, the increase of steroid hormones during
pregnancy could modify the maternal immune system and
contribute to the “tolerance” of the fetus but decrease the
ability to clear infections, including HPV [14].
Maternal infections, inflammation [15], and changes in
vaginal bacterial microbiota [16] have been recognized
as an underlying cause of major adverse pregnancy out-
comes (APO) such as miscarriage [17], spontaneous pre-
term birth [18], and pregnancy-related hypertension
disorders [19]. In particular, a recent large multicenter
study carried out across eight clinical sites in the USA
reported that infections/inflammation are involved in
38% of cases of spontaneous premature delivery [18].
This proportion could even be underestimated, as some
of pathogens are under detected because of the lack of
sensitivity of conventional detection techniques and diffi-
culties in taking informative samples when the infection is
intrauterine [15]. In addition, some genital infections re-
main asymptomatic and, as such, are not diagnosed [20].
Especially, HPV infections possess those peculiarities
in terms of long-term latency, episodic detectability, and
genital as well as intrauterine localization. Indeed, geni-
tal HPV infection may have a long-term clinical latency,
which either reflects the viral persistence (defined as two
or more HPV-positive tests over a certain period [21]) or
viral latency (HPV is not cleared but remains undetectable
by conventional molecular tests and can eventually reacti-
vate) [22]. Clinical latency may encompass episodic states
of viral clearance and recurrence, which can lead to misin-
terpretation of HPV infection status based only on one or
few HPV tests [23]. Furthermore, HPV has been localized
in amniotic fluid [24], in placental trophoblastic cells
[25, 26] and umbilical cord blood [26, 27]. Sometimes,
intrauterine infection does not necessary coincide with
cervical infection [25].
In vitro studies [28–30] and animal models [31–33]
demonstrated biological plausibility of detrimental effect
of HPV on pregnancy outcomes. These experimental
studies have shown that HPV can replicate in trophoblasts
[30] leading to (1) inhibition of blastocyst formation [32];
(2) failed or suboptimal endometrial implantation of
trophoblastic cells [29, 31]; and (3) apoptosis of embryonic
cells [33]. Besides these direct effects on placenta cells, it
has been hypothesized that HPV-trophoblast interaction
may trigger immune hypersensitivity to bacteria leading
to pregnancy complications, such as preeclampsia or
preterm labor [34].
Along with these experimental evidences, observational
studies have investigated the effect of HPV on APO, but
their results are equivocal. Some authors have concluded
to the association between HPV and APO [35–39],
whereas others have not found any association [40–43] or
have found that HPV is not an independent risk factor of
APO but could potentiate the harmful effect of other
genital infections on pregnancy [42, 44].
HPV infections can be a source of anxiety for pregnant
women and their family. Indeed, health professionals have
the task to answer questions and reassure HPV-positive
women attending antenatal clinics on the risk of APO re-
lated to HPV infection. With this kind of inconsistent
data, systematic reviews are recommended for identifica-
tion, appraisal, and synthesis of evidence in order to in-
form policy makers and clinicians [45].
Two reviews [46, 47] both published in 2014 have fo-
cused on the question of HPV and pregnancy complica-
tions. Bonde et al. reviewed the association between
HPV infection and infertility, APO, and the risk of verti-
cal transmission of HPV [46]. This review did not follow
any systematic approach to document and synthesize the
existing literature. After a narrative assessment of the lit-
erature, the authors concluded that more research was
necessary to reach firm conclusions on the association
between pregnancy outcomes and HPV [46]. Conversely,
Huang et al. conducted a meta-analysis and found a two-
fold increased risk of preterm birth in pregnant women
infected by HPV (pooled OR 2.12, 95% CI 1.51–2.98)
[47]. Although several subgroup analyses were conducted
to explore the substantial heterogeneity (I2 of 61%), this
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review still contained several limitations such as im-
portant exposure measurement bias. Indeed, in three of
eight included studies, HPV detection was prior to preg-
nancy [39, 48] or postnatal [37]. Given the high clearance
rate of HPV [8] and considering that pregnancy represents
the risk period, measuring exposure out of the pregnancy
period might lead to exposure measurement bias. How-
ever, the effect of this bias on the pooled estimate has not
been assessed.
In addition to the time point of HPV detection, other
factors, such as exposure measurement methods (cytology
vs HPV test) and characteristics of participants (e.g., other
genital infections) acting as confounding factors, could ex-
plain the substantial heterogeneity in this review and
could have led to a biased estimate. Also, the assessment
of confidence in cumulative evidence was limited to publi-
cation bias analysis. Finally, there could be residual con-
founding that may explain the large magnitude effect
reported by this meta-analysis.
Clinical trials have shown HPV vaccines to be highly
efficacious in preventing infections with the HPV types
targeted by the vaccines [49]. There is a growing litera-
ture on the promising benefits of HPV vaccination to
prevent HPV-related APO [50, 51]. In fact, widespread
implementation of HPV vaccination programs is expected
to reduce HPV prevalence and diseases related to HPV
[49, 52]. Especially, HPV vaccination is expected to reduce
incidence of cervical cancer and pre cancers, which will
reduce the need for cervical excision and therefore the
number of preterm birth [46, 50, 53]. However, there is in-
sufficient evidence on the potential harmful effect of HPV
on pregnancy outcomes to support this potential benefit
of HPV vaccine on pregnancy outcomes.
Given the rarity and limited quality of evidence of
previous reviews, there is a need to conduct a systematic
review using a clear and reproducible method taking into
account limitations of previous reviews (exposure window,
measurement of exposure, and uncontrolled confound-
ing). We will follow recommended guidelines to conduct
an extensive and systematic search, critically appraise and
summarize the search results and thoroughly assess the
quality of the overall evidence. We will also use sensitivity
analyses to assess the impact of potential limitations.
Thus, we will provide a better understanding of contra-
dictory previous studies and recent literature on the effect
of HPV infection on pregnancy outcomes. Ultimately, the
current review could shed light on the level of confidence
in overall evidence on the association between HPV infec-
tion and APO.
Objectives
Our main objective is to assess whether HPV infection
in pregnant women is associated with APO.
Methods
This protocol will follow the preferred reporting items
for systematic review and meta-analysis protocols
(PRISMA-P 2015) [54]. In interest of transparency and
completeness, a completed PRISMA-P 2015 checklist is
provided [see Additional file 1].
Eligibility criteria
The search strategy has been developed on the basis of
the PICOS framework: Population, Intervention (or Ex-
posure), Comparator, Outcomes and Study design.
Types of studies
We will include all types of observational studies: cohort
(retrospective and prospective), case-control, and cross-
sectional studies. We will also consider data from pla-
cebo groups of HPV vaccination randomized controlled
trials, which might have documented HPV-associated
APO.
Population of interest
We will include studies investigating APO in women
with and without HPV infection.
Exposure
The exposure of interest is the presence compared to the
absence of HPV infection in pregnant women. We will
consider HPV infection in all genital sites (vulva, vagina,
or cervix), in placenta, or other products of conception
(POC). The presence or absence of HPV infection will
need to have been proven by a sensitive molecular
method. We will include studies reporting either on over-
all HPV infection or on HPV type-specific infection.
Findings from in vitro studies and animal models
proved that HPV replication in the trophoblasts is the
principal cause leading to various HPV-related APO
[28–34]. Practically, it is difficult to distinguish the exact
exposure time window, which reflects the period during
which the exposure (HPV infection) is having its effects
relevant to the outcomes of interest (APO) [55]. We as-
sume that the pregnancy period represents the exposure
time window, which is the time period during which
HPV infection exerts its deleterious effect on pregnancy
outcome. Thus, we will include studies that reported
HPV infection during pregnancy. However, the median
duration of HPV infection has been estimated at ap-
proximately 12 months in a recent multi-country study
of healthy women aged over 25 years [8]. Consequently,
HPV infection detected prior to pregnancy may persist
during pregnancy and even after. Therefore, we will also
consider studies that reported HPV detection within
12 months prior to pregnancy and after delivery. The ef-
fect of these exposure window assumptions and inclusion
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of studies that used cytology as exposure measurement
will be assessed in sensitivity analyses.
Comparators
The comparison groups will include pregnant women
who are not infected by HPV, matched or not for known
possible confounders (age, smoking, alcohol, or other
genital infections). For the studies on HPV infection in
POC, comparators of concern will be POC in women
without HPV infection.
Outcomes and prioritization
Prioritization and definitions of the outcomes of interest,
with sources of definitions in brackets, are described
below:
Primary outcomes For the purpose of this review, we
will primarily focus on APO for which there is a plausible
biological HPV role suggested by in vitro studies. There-
fore, our main outcomes of interest will include the
following:
1. Pregnancy loss (or spontaneous abortion or
miscarriage), defined as a nonviable, intrauterine
pregnancy with either an empty gestational sac, or a
gestational sac containing an embryo or fetus
without fetal heart activity within the first 12 weeks
of gestation (early pregnancy loss) or within the first
20 weeks (late or second trimester pregnancy loss)
(ACOG: American College of Obstetricians and
Gynecologists) [56]
2. Preterm birth (PTB), defined as birth between 200/7
and 366/7 weeks of gestation (ACOG) [57]. Studies
without distinction between spontaneous and
elective preterm birth will be included. Where
feasible, this aspect will be assessed in subgroup or
sensitivity analysis.
Secondary outcomes Secondary outcomes consist of
APO that have been associated with maternal genital
viral infections in general [58] and with HPV in particular
[34] or have been linked to primary outcomes [59]. Thus,
we will include APO that may be associated with PTB (such
as pregnancy-induced hypertensive disorders (PIHD) [59,
60]) or that may be on the causal pathway of PTB (such as
preterm pre-labor rupture of membranes (PPROM) [61]. In
addition, secondary outcomes will include low birth weight
(LBW) as a proxy of PTB [59] and intrauterine growth re-
striction (IUGR) as a constituent of LBW [59]. We will in-
clude studies that reported on birth defects as almost 50%
of early miscarriages are due to chromosomal abnormalities
[56]. Likewise, we will consider stillbirths, which are related
to infection in general [62] and to most of previous APO
such as PIHD, IUGR, and PPROM [63].
The following APO will be considered as secondary
outcomes of interest:
1. LBW, defined as a weight of less than 2500 g
irrespective of the gestational age (WHO-ICD-10:
World Health Organization-International statistical
Classification of Diseases-tenth revision) [64].
2. PIHD, including preeclampsia/eclampsia and
gestational hypertension. Preeclampsia is a syndrome
defined by hypertension (blood pressure of
140 mmHg systolic or higher or 90 mmHg diastolic
or higher that occurs after 20 weeks of gestation in a
woman with previously normal blood pressure) and
proteinuria (urinary excretion of 0.3 g protein or
higher in a 24-h urine specimen). Eclampsia is defined
as the presence of new-onset grand mal seizures in a
woman with preeclampsia. The term gestational
hypertension refers to a woman who develops an
elevated blood pressure without proteinuria after
20 weeks of gestation and blood pressure levels
return to normal postpartum (ACOG) [65].
3. PPROM, defined as membrane rupture before labor
and before 37 weeks of gestation (ACOG) [66]
4. IUGR, defined as a fetus with an estimated fetal
weight <10th percentile at birth (SOGC: Society of
Obstetricians and Gynecologists of Canada) [67].
5. Birth defects. For practical reasons, we will focus on
birth defects that may be noticed at birth and for
which there are screening and diagnostic tests
during pregnancy [68].
6. Stillbirth, defined as fetal death that occurs during
pregnancy at 20 weeks of gestation or greater [63].
Settings
There will be no period or geographical restriction.
Language
There will be no language restriction provided that there
is an English or French abstract. Excluded English or
French relevant titles without English or French abstract
will be provided as an appendix.
Information sources
Our systematic search will target three information
sources. We will initially target MEDLINE, EMBASE, and
EBM Reviews databases (Cochrane Database of Systematic
Reviews, American College of Physicians- ACP- Journal
Club, Database of Abstracts of Reviews of Effects,
Cochrane Central Register of Controlled Trials, Cochrane
Methodology Register, Health Technology Assessment
and National Health Service –NHS- Economic Evaluation
Database). We will search MEDLINE (PubMed and Ovid
interfaces) from 1946, EMBASE from 1981, and EBM
(Ovid interface) from 1991 onwards.
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To ensure a complete search coverage, we will hand-
search reference lists of included titles and of any previ-
ous review related to our research question. Moreover,
we will search for additional relevant titles by screening
citations of included articles using Google Scholar or
Web of Science.
Finally, in order to identify unpublished studies, we will
search grey literature through Google Scholar and Web of
Science. Especially, we will search relevant conference
proceedings published on websites of international confer-
ences on HPV, such as IPV (International Papillomavirus)
and EUROGIN (European Research Organization on
Genital Infection and Neoplasia) conferences.
Search strategy
We will combine three systematic search strategies to
identify relevant literature. Initially, for each of electronic
databases, a specific search strategy was developed. We
have first developed a search strategy for MEDLINE based
on Medical Subject Headings (MeSH) and free text words.
Our research team developed the terms for MEDLINE on
the basis of the eligibility criteria. The search strategy was
developed by the principal author (JN) and a health sci-
ences librarian with expertise in systematic literature
searching. We combined terms (or exploded terms where
possible) using Boolean operators. Terms developed in
MEDLINE were adapted for correct use in the EMBASE
and EBM Reviews databases. Preliminary search strategies
piloted for PubMed, EMBASE, and EBM Reviews data-
bases are provided [see Additional file 2].
The second search strategy will target grey literature
to identify additional unpublished articles in journals
indexed in electronic databases. To maximize identifica-
tion of more relevant studies, we will combine three
complementary grey literature online sources, namely
Google Scholar, Web of Science conference proceedings
citation index, and International conferences specific
websites. Thus, we will search Google Scholar using the
following free text words: “pregnancy outcomes” and
“papillomavirus”. We will retain relevant unpublished ti-
tles, which will be screened according to the eligibility
criteria. The same search terms used for MEDLINE will
be adapted for Web of Science. We will apply filters
within Web of Science search strategy to restrict results
to conference proceedings. In addition, we will hand-
search for relevant conference proceedings of not formally
published studies through online abstract books of IPV
and Eurogin conferences.
The third search strategy will target additional relevant
titles by searching citations of included articles and of
any previous review. We will screen reference lists of in-
cluded studies and previous reviews to find relevant
cited articles. We will use Google Scholar (or Web of
Science) to find citing publications of included articles.
Citing and cited articles will be screened using the same




All titles identified from electronic databases (MEDLINE,
EMBASE, and EBM Reviews databases) will be uploaded
and combined into an EndNote file (EndNote X7.3). Titles
retrieved from Grey literature will be manually entered
into EndNote file or uploaded individually from Google
Scholar. Using EndNote’s auto-deduplication function, we
will first automatically find and remove duplicate publica-
tions. To avoid any residual duplicate, we will sort the
remaining records by author’s names and later by titles.
For the sake of clarity, all duplicates will be kept into du-
plicate EndNote subfolder. After duplicates are removed,
all remaining records will be saved into an EndNote
subfolder.
Selection process
Two authors JN and NZ will independently and in dupli-
cate screen the remaining records in two phases.
At the first phase (screening), a standardized checklist
created on the basis of eligibility criteria will be used to
screen titles and abstracts [see Additional file 3]. The
screening phase will differentiate potentially eligible from
non-eligible studies. Thus, study’s title or abstract that
clearly does not pertain to any of PICOS criteria will be
excluded. Studies that cannot be clearly excluded on the
basis of title or abstract (uncertain and eligible) will be
retained for further assessment.
At the second phase (eligibility), full text reports of all
potentially eligible records will be retrieved and independ-
ently analyzed by the same two reviewers. A standardized
form with explicit and detailed eligibility criteria on the
basis of PICOS will be used to screen full text reports [see
Additional file 4].
With the aim of reducing errors, a pilot test of the
standardized tools will be conducted prior to the complete
selection process. At each selection step, a random sample
of 10% of the records will be used to test screening and
eligibility tools. Disagreements will be resolved by discus-
sion between the two reviewers. Any persisting discrep-
ancy will be discussed with the senior researchers (HT and
MHM).
In the interest of transparency, a list of excluded stud-
ies after full text assessment and detailed reasons of ex-
clusion will be provided in review additional files. A
PRISMA flow diagram will summarize the entire selection
process. For each selection step, the flow diagram will in-
dicate the number of retained and excluded records with a
short description of the reasons for exclusion.
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Data collection process
Data will be extracted from selected studies using a stan-
dardized form adapted from the Effective Practice and
Organization of Care (EPOC) data collection form [69]
(Additional file 4). To minimize errors in data collection,
a pilot test of standardized form will be conducted on a
random sample of 10% of included studies. The form
will be revised as needed to insure that relevant informa-
tion is collected. The two first reviewers will independ-
ently and in duplicate extract data from full text reports
of included studies. Discrepancies will be resolved through
consensus and if necessary by discussion with a third se-
nior author. In the absence of important information
(such as the number of APO and total sample size), we
plan to contact (with a maximum of three email attempts)
the primary author of included studies to obtain missing
data.
Data items
Extracted data will include, but not be limited to, study
characteristics (first author name, country, and year of
publication), methods (aim of study, design, unit of ob-
servation, definition of APO), participants’ characteristics
(source population description, inclusion and exclusion
criteria, methods of recruitment, sample size, average
age, HPV detection procedures, time of HPV detection),
and number of each APO within HPV-exposed and HPV-
unexposed groups. HPV genotypes will be extracted when
possible. Some studies may include a composite measure
of APO. We will extract, if possible, frequency of each
APO from the composite outcome. If the information on
each component of composite outcome is not available,
we plan to contact the primary author to obtain missing
data (with a maximum of three email attempts); otherwise,
we will report the composite outcome with its definition
provided in individual studies.
Risk of bias in individual studies
We will use the Effective Public Health Practice Project
(EPHPP) Quality Assessment Tool for Quantitative Stud-
ies to evaluate methodological quality and risk of bias of
included studies. The EPHPP is a standardized tool rele-
vant to evaluate quality of quantitative observational stud-
ies [70]. This quality assessment tool mainly encompasses
the Strengthening the Reporting of Observational Studies
in Epidemiology (STROBE) checklist. The EPHPP has
acceptable content and construct validity [71] as well as
excellent inter-rater reliability compared to the Cochrane
Collaboration Risk of Bias Tool (CCRBT) [70]. The EPHPP
tool evaluates six domains of study validity: selection
bias, study design, confounders, blinding, data collec-
tion method, and withdrawals/dropouts [72]. Each of
six domains can be rated as strong, moderate, or weak.
Based on individual domain ratings, the quality of each
included study will be globally scored as either (1)
strong (no weak individual domain rating); (2) moderate
(one weak individual domain rating), or (3) weak (two or
more weak individual domains ratings) [72]. This bias and
quality assessment will be independently and in duplicate
carried out by the two first reviewers. We will compute
agreement in individual domain ratings between reviewers
for each included primary study based on the Cohen
kappa coefficient. Discrepancies and study component
ratings with kappa values below 0.80 will be resolved
through discussion. Unresolved disagreement will be
discussed with a third author. Differences among stud-
ies revealed by quality assessment of primary studies
will guide, where appropriate, subsequent subgroup, or
sensitivity analyses [73].
Data synthesis
The purpose of our data synthesis will be twofold: (1) a
narrative synthesis through which we will summarize
and discuss findings of included studies and (2) a statis-
tical analysis whereby we will investigate relationship be-
tween APO and HPV infection.
Narrative synthesis
We will narratively synthesize included studies whether
meta-analysis is appropriate or not. For the purpose of
transparency and reproducibility, we will adopt, where
applicable, the narrative synthesis guidance proposed by
Popay et al. [74]. The guidance describes a framework of
four elements on which the narrative synthesis may be
based: (1) developing a theory of how the intervention
works, why, and for whom, (2) developing a preliminary
synthesis of findings of included studies, (3) exploring
relationships within and between studies, and (4) asses-
sing the robustness of the synthesis. It is not required to
proceed linearly or to apply all four elements in narra-
tive synthesis. However, one chooses the elements to be
employed depending on the nature of research question
being reviewed [75]. According to the objective of this
review, we plan to use only the 2nd and 3rd elements of
this guideline.
We will initially present findings first by primary out-
comes and then by secondary outcomes. We will use
tabular summary to synthesize individual studies charac-
teristics and results (direction and magnitude of effects).
In addition, we will explore factors, which might explain
differences in direction and size of effect within the in-
cluded studies [45, 74]. With particular consideration to
potential confounders, we will assess results in light of
participant’s characteristics and exposure measurement
differences. Without computing a pooled estimate, we will
visually assess the dispersion of effect estimates from pri-
mary studies using forest plots. We will finally conclude
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the narrative synthesis by an assessment of publication
bias and strength of overall evidence.
Statistical analysis
We anticipate that there will be much variability between
included studies because of clinical diversity (variability in
the characteristics of participants, exposure measurement
and outcomes) and methodological diversity (variability in
study design and risk of bias). Thus, we will conduct a
meta-analysis using Der Simonian-Laird random-effects
model for each primary and secondary outcome [76]. We
assume that included studies will report dichotomous out-
comes data from HPV-exposed and HPV-non-exposed
pregnant women or products of conception. We will then,
for each study, compute a weighted measure of associ-
ation as relative risk (RR) estimated with the comparison
of exposed women to unexposed women. However, it is
worth mentioning that focusing data analysis solely on the
average measure of random effects may be misleading
[77]. We will therefore put emphasis on the analysis of the
dispersion of the measures of association of individual
studies rather than focusing on summary estimates yielded
by meta-analyses. This analysis will be focused, but not be
limited, to the assessment of the extent of inconsistency,
the amount of dispersion, and the causes of heterogeneity.
Particularly, heterogeneity assessment will include investi-
gation of the effect of the major limitations of previous re-
views: exposure window, measurement of exposure, and
uncontrolled confounding. All statistical analyses will be
conducted using STATA 14 (StataCorp. 2015. Statistical
Software: Release 14. College Station, TX: StataCorp LP.).
1. Assessment of the extent of inconsistency
We will use forest plots to represent the dispersion
of observed RRs. Along with the forest plot, we will
compute I2 statistic (with its 95% CI) to formally
quantify the proportion of variance in observed RRs
that reflects the true heterogeneity between studies
rather than chance [45]. According to criteria of
Higgins et al., we will consider I2 of more than 50%
as substantial heterogeneity [45].
2. Assessment of the amount of dispersion
In addition to I2, we will report T2 statistic as the
absolute amount of dispersion of true effects,
especially in case of meta-analyses with few studies
[77]. We will also compute the 95% prediction interval
to estimate the range within which a hypothetical new
true measure of association is expected to be found in
95 of 100 cases [77]
3. Investigating the causes of heterogeneity and
limitations of previous reviews:
(a)Subgroup analyses and meta-regression
We will investigate through subgroup analyses
how clinical and methodological variability
influence the pooled measure of association.
Although both clinical and methodological
diversity lead to statistical heterogeneity [45], we
assume that clinical factors may vary more across
included studies than methodological factors.
Thus, clinical diversity could be more prone to
affect clinical meaningful of an average summary
estimate and heterogeneity than methodological
diversity. Subgroup analyses will therefore be
focused on the assessment of the effect of key
characteristics of participants identified from
literature, which may be associated with the
primary outcomes of interest and uncontrolled in
previous reviews. Thus, we will conduct subgroup
analyses based, but not limited to, maternal age,
parity, race, smoking, drug use, genital infections,
and prior APO. We will also group and compare
studies that have matched/controlled and not
matched/not controlled data on some of these
key variables (age, parity, and smoking). Where
appropriate, we will conduct a meta-regression
on the basis of study average or proportion values
of key participant’s characteristics.
(b)Sensitivity analyses
We will assess robustness of our findings by
restricting the analysis to a subset of studies
with high or moderate quality based on EPHPP
score. Sensitivity analysis will be undertaken to
take into account quality relative to
confounding bias by stratification of most
adjusted and least adjusted estimates from each
study. Similarly, we plan to assess the effect of
time point detection of HPV by restricting
analysis to different alternative exposure
windows (12 months prior to pregnancy,
pregnancy period, or 12 months postpartum).
Finally, we will investigate the extent to which
inclusion of studies that used cytology as
exposure measurement affects the results.
Meta-biases assessment
If there are at least 10 studies for each outcome, we
will use funnel plot to explore the potential of publica-
tion bias and small studies effect [45]. Additionally,
Egger’s test for funnel plot asymmetry will be con-
ducted [45]. However, in case of less than 10 studies,
we will assess qualitatively the small study effect. For
this purpose, we will perform a cumulative meta-
analysis sorting studies from largest to smallest study
to examine the effect of study size on the pooled esti-
mate [78]. We will assess selective reporting within in-
cluded studies by comparing outcomes reported in
methods and results sections [79].
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Confidence in cumulative evidence
We will use the Grading of Recommendations Assess-
ment, Development and Evaluation (GRADE) approach
to assess and grade the confidence of evidence for each
outcome across included studies [80]. Quality rating of
overall evidence will be downgraded according to five
factors: (1) limitations in the design (risk of bias across
studies); (2) indirectness (exposure or outcomes are dif-
ferent from those defined in inclusion criteria of this
protocol); (3) unexplained heterogeneity (after subgroup
analyses); (4) imprecision of effect estimates (few partici-
pants or few events); and (5) risk of publication bias [45]
[80]. In addition and where appropriate, quality rating
will be upgraded according to the following three fac-
tors: (1) a large magnitude of effect, (2) a dose response
gradient (e.g., the more types of HPV are identified, the
high is the risk of pregnancy outcome), and (3) plausible
residual confounding that would reduce a demonstrated
effect or suggest a spurious effect when results show no
effect [45].We will integrate downgrading and upgrading
factors to obtain an overall quality of evidence for each
outcome of interest. Overall quality of evidence will be
then ranked as high, moderate, low, or very low as speci-
fied by GRADE approach [80]. However, in order to be
more explicit about overall level of confidence of our
findings, we will translate GRADE levels into categories
suggested by Young et al. [81] as high (further research
is very unlikely to change our confidence in the estimate
of effect), moderate (further research is likely to have an
important impact on our confidence in the estimate of
effect and may change the estimate), low (further re-
search is very likely to have an important impact on our
confidence in the estimate of effect and is likely to
change the estimate), or very low (very uncertain about
the estimate of effect). Finally, key information concern-
ing the quality of evidence of all outcomes will be con-
cisely combined in “summary of findings” table.
Discussion
This review will rely only on observational studies,
which are prone to confounding biases. Moreover, we
expect that there will be much heterogeneity in included
studies in terms of study design, exposure measurement,
characteristics of participants, and outcomes. Neverthe-
less, to our knowledge, this will be the first review that
will use a validated systematic and transparent methodo-
logical process to appraise and summarize the existing
literature on HPV-associated pregnancy outcomes. Thus,
whatever conclusion our study reaches (harmful effect,
absence of effect, or uncertain effect), we are confident
that this review will provide rigorous and comprehensive
high-quality evidence related to HPV-associated preg-
nancy outcomes. Indeed, we expect that our findings will
ultimately fall into one of the following three scenarios.
Firstly, if our findings are in favor of a harmful effect of
HPV infection on pregnancy outcomes, this might ex-
plain a part of APO so far classified as idiopathic. There-
fore, the fact that HPV infection might explain some
APO could strengthen primary prevention through vac-
cination. Secondarily, in case of absence of relationship,
this might dispel anxiety and reassure HPV-infected
pregnant women and health professionals. Thirdly, if
ever we end up being uncertain of the effect, we will
provide an overview of gaps in current knowledge and
propose further research directions on HPV-pregnancy
outcome relationship.
Dissemination of findings
We will report this review in accordance to the Meta-
analysis of Observational Studies in Epidemiology (MOOSE)
guidelines [82] and the Preferred Reporting Items for
Systematic Reviews and Meta-analyses (PRISMA) [83].
This systematic review will be part of JN’s PhD research
thesis co-supervised by HT and MHM. This systematic
review will also be submitted for publication in a relevant
peer-reviewed journal, and findings will be presented in
scientific conferences.
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